Table 2.

CMR-based volumetric measurements of all patients with left ventricular hypertrophy (LVH), patients with LVH and confirmed etiology of hypertrophic cardiomyopathy (LVH+ HCM+) and patients with LVH and a mimicking cardiomyopathy state (LVH+ HCM–).

		LVH+ HCM+	LVH+HCM–
	All patients	HCM	All LVH+HCM–	CA	AFD	HTNcm
Parameter	(N = 163)	(N = 85)	(N = 78)	(N = 18)	(N = 30)	(N = 30)	p-Value	AUC (95% CI)
LVEDVI (mL/m2)	78.4 ± 18.0	81.0 ± 15.1	75.5 ± 20.4**	80.8 ± 29.6	75.0 ± 15.3	72.9 ± 18.3*	0.1	0.65 (0.51–0.80)
LVESVI (mL/m2)	25.7 ± 12.2	24.6 ± 8.4	27.0 ± 15.3	37.0 ± 25.3*	25.1 ± 8.4	22.9 ± 9.5	0.1	–
LVEF (%)	67.8 ± 9.4	70.0 ± 7.5	65.4 ± 10.7*	56.4 ± 15.6***	66.8 ± 6.5	69.3 ± 7.4	0.001	0.60 (0.50–0.70)
LVMI (g/m2)	80.2 ± 24.6	84.2 ± 26.3	75.9 ± 21.8*	84.2 ± 28.3	65.4 ± 17.3***	81.5 ± 17.6	<0.005	0.60 (0.49–0.70)
RVEDVI (mL/m2)	78.5 ± 20.7	75.1 ± 15.7	82.2 ± 24.6	91.4 ± 32.5**	79.8 ± 19.8	78.9 ± 22.9	0.3	–
RVESVI (mL/m2)	31.7 ± 14.1	28.1 ± 8.8	35.6 ± 17.4**	46.4 ± 25.7***	31.9 ± 12.1	32.9 ± 13.1	0.005	0.62 (0.49–0.70)
RVEF (%)	60.4 ± 9.0	62.8 ± 7.5	57.7 ± 9.7***	51.1 ± 11.5****	60.8 ± 8.0	58.7 ± 8.3*	<0.0001	0.68 (0.54–0.80)
LAEDVI (mL/m2)	91.5 ± 35.6	103.7 ± 38.5	78.0 ± 26.3****	89.4 ± 27.6	66.5 ± 20.4****	83.0 ± 27.2**	<0.0001	0.70 (0.54–0.90)

AFD, Anderson-Fabry Disease; CA, cardiac amyloidosis; HCM, hypertrophic cardiomyopathy; HTNcm, hypertensive hypertrophy; LAEDVI, left-atrial end-diastolic volume; LVEDVI, left-ventricular end-diastolic volume index; LVEF, left-ventricular ejection fraction; LVH, left-ventricular hypertrophy; LVMI, left-ventricular mass index; LVESVI; left-ventricular end-systolic volume index; RVEDVI, right-ventricular end-diastolic volume index; RVEF, right-ventricular ejection fraction; RVESVI, right-ventricular end-systolic volume index.

Vs. HCM:

^*<0.05.

^**<0.01.

^***<0.001.

^****<0.0001.

Bold values are used for specific headers or p-Values lower than 0.05 (i.e. statistical significance).